Table 1.
Demographics and clinical characteristics of patients with low-grade gliomas.
| Epilepsy recurrence | Non-epilepsy recurrence | P | |
|---|---|---|---|
| Age (mean ± deviation) | 37.667 ± 9.651 | 38.101 ± 9.517 | 0.802 |
| Sex | 0.856 | ||
| Male | 30 | 49 | |
| Female | 21 | 30 | |
| Tumor location | 0.365 | ||
| Frontal lobe | 36 | 60 | |
| Temporal lobe | 23 | 22 | |
| Parietal lobe | 4 | 9 | |
| Insula | 8 | 9 | |
| Preoperative epilepsy | 0.342 | ||
| Yes | 39 | 53 | |
| No | 12 | 26 | |
| Tumor pathology | 0.725 | ||
| Diffuse Astrocytoma | |||
| IDH-mutant with 1p/19q no-deleted | 17 | 31 | |
| IDH-wildtype | 10 | 13 | |
| Oligodendroglioma | |||
| IDH-mutant with 1p/19q co-deleted | 16 | 27 | |
| NOS | 8 | 8 | |
| IDH status | 0.875 | ||
| IDH-mutant | 41 | 64 | |
| IDH-wildtype | 10 | 13 |
The status of epilepsy recurrence is determined at 24 months. The location of the tumor is determined by the region of the tumor involved, where some patients have tumors involving multiple regions. Chi-Square test or Student's t-test were used to compare the differences between epilepsy and non-epilepsy groups.